3,4-Methylenedioxymethamphetamine quantification via benchtop 1H qNMR spectroscopy: Method validation and its application to ecstasy tablets collected at music festivals.
Journal of pharmaceutical and biomedical analysis May 30, 2022 Anca Frinculescu, Alexander F G Maier, Trevor Shine et al.
A method for measuring MDMA content in ecstasy tablets using a compact 60 MHz benchtop NMR spectrometer was validated against UNODC guidelines. The method showed good specificity, selectivity, linearity, precision, and accuracy. Among seized tablets, the lowest MDMA free base detected was 9.35 mg in a piperazine mix, and the highest was 237.55 mg. The median MDMA amount in 2022 was 9.1% lower than pre-pandemic 2019 data but still higher than the 105 mg median reported in 2018. Within-batch variation was insignificant for one seizure but greater for another, indicating a single tablet's content may not represent the whole batch. The upward dosage trend underscores the need for ongoing monitoring and prevention interventions.